Health care utilization and costs of systemic lupus erythematosus in the United States: A systematic review.


Journal

Lupus
ISSN: 1477-0962
Titre abrégé: Lupus
Pays: England
ID NLM: 9204265

Informations de publication

Date de publication:
Jun 2022
Historique:
pubmed: 26 4 2022
medline: 18 5 2022
entrez: 25 4 2022
Statut: ppublish

Résumé

To evaluate health care utilization and costs for patients with systemic lupus erythematosus (SLE) by disease severity. We searched PubMed and Embase from January 2000 to June 2020 for observational studies examining health care utilization and costs associated with SLE among adults in the United States. Two independent reviewers reviewed the selected full-text articles to determine the final set of included studies. Costs were converted to 2020 US $. We screened 9224 articles, of which 51 were included. Mean emergency department visits were 0.3-3.5 per year, and mean hospitalizations were 0.1-2.4 per year (mean length of stay 0.4-13.0 days). Patients averaged 10-26 physician visits/year. Mean annual direct total costs were $17,258-$63,022 per patient and were greater for patients with moderate or severe disease ($19,099-$82,391) compared with mild disease ($12,242-$29,233). Mean annual direct costs were larger from commercial claims ($24,585-$63,022) than public payers (Medicare and Medicaid: $18,302-$27,142). SLE remains a significant driver of health care utilization and costs. Patients with moderate to severe SLE use more health care services and incur greater direct and indirect costs than those with mild disease.

Identifiants

pubmed: 35467448
doi: 10.1177/09612033221088209
doi:

Types de publication

Journal Article Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

773-807

Auteurs

Dora H Lin (DH)

Department of Epidemiology, 25802Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

Irene B Murimi-Worstell (IB)

Department of Epidemiology, 25802Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

Hong Kan (H)

Department of Health Policy and Management, 25802Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

Jonothan C Tierce (JC)

Department of Epidemiology, 25802Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

Xia Wang (X)

Data Science & Artificial Intelligence, BioPharmaceuticals R&D, 468090AstraZeneca, Gaithersburg, MD, USA.

Henk Nab (H)

Inflammation & Autoimmunity, BioPharmaceuticals Medical, 468087AstraZeneca, Cambridge, UK.

Barnabas Desta (B)

Global Pricing and Market Access, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD, USA.

Edward R Hammond (ER)

Epidemiology, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD, USA.

G Caleb Alexander (GC)

Center for Drug Safety and Effectiveness, 25802Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH